Health News Round-Up: FDA Approvals and Market Movements

The latest health news includes Church & Dwight adjusting forecasts due to cautious consumer spending, FDA's approval of Adaptimmune's new cancer therapy, and the availability updates of Eli Lilly's weight-loss and diabetes drugs. The updates reflect significant trends and developments in the health sector.

The latest developments in health news reveal significant shifts and approvals that could impact the industry.

Church & Dwight has adjusted its full-year sales and profit forecasts downward due to consumer caution on spending for its premium household and personal care products, leading to a 4.3% drop in premarket shares for the Trojan condom maker.

The US FDA has given the green light to Adaptimmune's groundbreaking treatment, Tecelra, for a rare cancer affecting soft tissues, specifically synovial sarcoma. This approval offers new hope for patients who have undergone prior chemotherapy.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are now fully available, according to the FDA's latest update, though the drugs remain on the shortage list.

(With inputs from agencies.)